Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 20.04% is 59% above its 5-year average of 12.63%, near the high end of its 5-year range (3.21%–25.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 184.32% above its 12-month average of 7.05%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 20.04%.
DEBT TO ASSETS RATIO
20.04%
DEBT TO ASSETS RATIO AVG TTM
7.05%
DEBT TO ASSETS RATIO AVG 3Y
3.62%
DEBT TO ASSETS RATIO AVG 5Y
12.63%
DEBT TO ASSETS RATIO AVG 10Y
16.90%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+184.32%
CURRENT VS 3Y AVG
+454.30%
CURRENT VS 5Y AVG
+58.72%
CURRENT VS 10Y AVG
+18.60%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+22166.65%
vs the sector median at left
Cartesian Therapeutics, Inc.
Market Cap
$204.79M
Debt to Assets Ratio
20.04%
TTM Avg
7.05%
3Y Avg
3.62%
5Y Avg
12.63%
Market Cap
$206.24M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.37M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.73M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.21M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $204.79M | 20.04% | 7.05% | 3.62% | 12.63% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.24M | 0.00% | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.37M | 0.03% | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $202.17M | 0.49% | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $201.52M | 0.05% | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.55M | 0.24% | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $200.97M | 0.16% | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.73M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.21M | 0.16% | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.37M | 0.02% | N/A | N/A | N/A |
Debt/Assets
20.0%
Debt/Equity
N/A
Current Ratio
7.48
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 20.04% |
| 2026-03-31 | 4.11% |
| 2025-12-31 | 4.28% |
| 2025-09-30 | 3.38% |
| 2025-06-30 | 3.43% |
| 2025-03-31 | 3.44% |
| 2024-12-31 | 3.21% |
| 2024-09-30 | 3.22% |
| 2024-06-30 | 4.28% |
| 2024-03-31 | 3.22% |
| 2023-12-31 | 3.59% |
| 2023-09-30 | 9.88% |
| 2023-06-30 | 25.03% |
| 2023-03-31 | 24.24% |
| 2022-12-31 | 22.86% |
| 2022-09-30 | 21.40% |
| 2022-06-30 | 18.64% |
| 2022-03-31 | 24.12% |
| 2021-12-31 | 22.07% |
| 2021-09-30 | 21.13% |
| 2021-06-30 | 19.58% |
| 2021-03-31 | 20.00% |
| 2020-12-31 | 21.37% |
| 2020-09-30 | 19.53% |
| 2020-06-30 | 35.37% |
| 2020-03-31 | 32.36% |
| 2019-12-31 | 19.36% |
| 2019-09-30 | 54.78% |
| 2019-06-30 | 48.21% |
| 2019-03-31 | 36.64% |
| 2018-12-31 | 48.08% |
| 2018-09-30 | 35.31% |
| 2018-06-30 | 28.88% |
| 2018-03-31 | 23.49% |
| 2017-12-31 | 20.81% |
| 2017-09-30 | 19.10% |
| 2017-06-30 | 8.84% |
| 2017-03-31 | 15.42% |
| 2016-12-31 | 13.49% |
| 2016-09-30 | 13.96% |
| 2016-06-30 | 13.04% |
| 2016-03-31 | 34.10% |
| 2015-12-31 | 27.68% |
